Penumbra (PEN) Stock Forecast, Price & News

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Penumbra in the last year. There are currently 1 hold rating and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PEN shares.
View PEN analyst ratings or view top-rated stocks.

12 equities research analysts have issued 1 year target prices for Penumbra's shares. Their PEN share price forecasts range from $185.00 to $350.00. On average, they anticipate the company's stock price to reach $296.33 in the next year. This suggests that the stock has a possible downside of 3.3%.
View analysts price targets for PEN or view top-rated stocks among Wall Street analysts.

Penumbra's stock was trading at $222.46 at the start of the year. Since then, PEN stock has increased by 37.8% and is now trading at $306.50.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our PEN earnings forecast.

Penumbra, Inc. (NYSE:PEN) announced its quarterly earnings data on Tuesday, May, 2nd. The company reported $0.23 EPS for the quarter, topping the consensus estimate of $0.11 by $0.12. The firm earned $241.40 million during the quarter, compared to analysts' expectations of $229.70 million. Penumbra had a net margin of 0.73% and a trailing twelve-month return on equity of 1.58%. Penumbra's revenue for the quarter was up 18.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.01) earnings per share.

ETFs with the largest weight of Penumbra (NYSE:PEN) stock in their portfolio include MFAM Small-Cap Growth ETF (MFMS), Motley Fool Small-Cap Growth ETF (TMFS), Pinnacle Focused Opportunities ETF (FCUS), Invesco DWA Healthcare Momentum ETF (PTH), Global X Founder-Run Companies ETF (BOSS), Alger Mid Cap 40 ETF (FRTY), ROBO Global Healthcare Technology and Innovation ETF (HTEC) and First Trust Health Care AlphaDEX Fund (FXH).

Penumbra issued an update on its FY 2023 earnings guidance on Wednesday, May, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.04 billion-$1.06 billion, compared to the consensus revenue estimate of $1.01 billion.

57 employees have rated Penumbra Chief Executive Officer Adam Elsesser on Glassdoor.com. Adam Elsesser has an approval rating of 88% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Penumbra investors own include NVIDIA (NVDA), Intuitive Surgical (ISRG), AbbVie (ABBV), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Netflix (NFLX), UnitedHealth Group (UNH), Boeing (BA) and DexCom (DXCM).

Penumbra trades on the New York Stock Exchange (NYSE) under the ticker symbol "PEN."

Penumbra's stock is owned by many different retail and institutional investors. Top institutional shareholders include FMR LLC (14.69%), BlackRock Inc. (11.58%), Price T Rowe Associates Inc. MD (5.71%), State Street Corp (2.73%), Clearbridge Investments LLC (2.48%) and William Blair Investment Management LLC (2.46%). Insiders that own company stock include Adam Elsesser, Arani Bose, Bridget O'rourke, Don W Kassing, Don W Kassing, Harpreet Grewal, James Robert Pray, Johanna Roberts, Lynn Rothman, Surbhi Sarna and Thomas Wilder.
View institutional ownership trends.

Shares of PEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PEN stock can currently be purchased for approximately $306.50.

Penumbra (NYSE:PEN) has a market capitalization of $11.72 billion and generates $847.13 million in revenue each year. The company earns $-2,000,000.00 in net income (profit) each year or $0.16 on an earnings per share basis.

The company employs 3,900 workers across the globe.

Penumbra's mailing address is One Penumbra Place, Alameda CA, 94502. The official website for the company is www.penumbrainc.com. The company can be reached via phone at (510) 748-3200, via email at investors@penumbrainc.com, or via fax at 510-748-3232.